Johnson & Johnson (NYSE: JNJ) is a global healthcare company operating as a pure-play pharmaceutical and medical-technology business following the 2023 spin-off of its consumer health division into Kenvue. This page brings together live JNJ market data, charting, financials, technical indicators, company details, recent news and a clearly labelled Shariah-screening snapshot for research purposes. Market data and widgets below update dynamically; Shariah status should be treated as time-sensitive and independently verified.
Key Investor Considerations for Johnson & Johnson
Potential Strengths
- Diversified across two distinct healthcare segments — Innovative Medicine and MedTech — reducing reliance on any single therapeutic area
- Patent-protected pipeline across oncology, immunology, neuroscience, cardiovascular/metabolism, pulmonary hypertension and infectious diseases
- Simplified, focused business structure following the 2023 Kenvue consumer-health spin-off
- One of the market’s longest dividend-increase streaks, spanning more than six decades
- Strong balance sheet and continued investment in R&D and pipeline-expanding acquisitions
- MedTech franchise spans surgery, orthopaedics, cardiology and vision care, providing diversification beyond pharmaceuticals
Material Risks
- Patent expirations and loss-of-exclusivity risk facing key products over time
- Ongoing product-liability litigation exposure, which investors should track through official disclosures rather than assume is resolved
- Clinical and regulatory failure risk inherent to pipeline assets in development
- Intense competition from Pfizer, Merck, AbbVie, Medtronic and Stryker across its therapeutic and device categories
- Pricing and reimbursement pressure from healthcare payers and regulatory reform
- Integration risk associated with pipeline-expanding acquisitions
Frequently Asked Questions
What does Johnson & Johnson do?
Johnson & Johnson is a global healthcare company operating across Innovative Medicine (pharmaceuticals spanning oncology, immunology, neuroscience and other therapeutic areas) and MedTech (surgical, orthopaedic, cardiology and vision-care devices), following the 2023 spin-off of its consumer health business into Kenvue.
On which exchange is Johnson & Johnson listed?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol JNJ.
What are Johnson & Johnson’s main business segments?
Johnson & Johnson reports two segments: Innovative Medicine, covering oncology, immunology, neuroscience, cardiovascular and metabolism, pulmonary hypertension and infectious diseases, and MedTech, covering surgery, orthopaedics, cardiology and vision care.
Is Johnson & Johnson still involved in consumer products like Band-Aid and Tylenol?
No. Johnson & Johnson completed the spin-off of its consumer health division into an independent public company, Kenvue, in 2023. Johnson & Johnson now operates as a pure-play pharmaceutical and MedTech company.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson has increased its dividend annually for more than six decades, among the longest active streaks in the market. Investors should verify the current payout through Johnson & Johnson’s investor relations page before relying on it.
Who are Johnson & Johnson’s main competitors?
Johnson & Johnson competes with Pfizer, Merck and AbbVie in pharmaceuticals, and with Medtronic and Stryker in medical technology and devices.
Is Johnson & Johnson stock currently Shariah compliant?
Zoya screens JNJ as Shariah-compliant under AAOIFI standards, citing interest income of roughly 1.12% of combined revenue. This page checked only Zoya as a screening source; investors should confirm current status through a named provider or qualified Shariah adviser before relying on it.
Conclusion
Johnson & Johnson has emerged as a focused, pure-play healthcare company following the 2023 spin-off of its consumer health business into Kenvue, built around a patent-protected Innovative Medicine pipeline spanning oncology, immunology and neuroscience alongside a diversified MedTech franchise in surgery, orthopaedics, cardiology and vision care. That position is balanced against patent-expiration and loss-of-exclusivity risk, ongoing product-liability litigation exposure, and intense competition from Pfizer, Merck, AbbVie, Medtronic and Stryker. The tools on this page — charts, financials, technical indicators and news — support ongoing research into Johnson & Johnson’s position, but they do not replace a review of Johnson & Johnson’s official filings or independent financial, legal, tax or Shariah advice.